Disc Medicine Faces FDA Setback for Bitopertin in EPP Treatment
Disc Medicine received an FDA Complete Response Letter for bitopertin, targeting erythropoietic protoporphyria (EPP). Despite showing PPIX reduction, trials lacked proof of clear clinical benefits, delaying approval and causing stock fluctuation.